The Global Neuromodulation Market size is expected to reach $3. 8 billion by 2028, rising at a market growth of 6. 0% CAGR during the forecast period. Neuromodulators are a type of neurotransmitter that is a subgroup of neurotransmitters.
New York, June 14, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Neuromodulation Market Size, Share & Industry Trends Analysis Report By Technology, By Biomaterial, By Application, By Regional Outlook and Forecast, 2022 – 2028" - https://www.reportlinker.com/p06283452/?utm_source=GNW Neuromodulators, unlike neurotransmitters, are released in a diffused way. This indicates that exposure to the neuromodulator could expose a complete neural tissue to its effects. As a result, the neuronal circuitry of an entire brain region, rather than simply a single neuron, may be tuned. The growing incidence of various types of neurological illnesses, such as Alzheimer’s disease, dementia, stroke, and brain tumors, is driving the expansion of the neuromodulation market. The increase in the prevalence of brain illnesses and the use of neuromodulation devices in developed nations are both contributing to the expansion of the neuromodulation market share. Deep brain stimulation (DBS) is a technique for treating epilepsy and Parkinson’s disease. The market for neuromodulation is growing as the prevalence of epilepsy rises. Epilepsy, for example, is a chronic non-communicable brain disorder that affects people of all ages, according to the World Health Organization (WHO) in February 2022. According to the same source, around 50 million people across the world have been diagnosed with epilepsy. Furthermore, the increase in the geriatric population aided the market’s expansion. Alzheimer’s along with other neurological disorders are more common in the elderly population. According to the Alzheimer’s Association, a non-profit organization, approximately 6.2 million Americans aged 65 and older were diagnosed with Alzheimer’s dementia in 2021. COVID-19 Impact Since most hospitals are closed owing to continuous lockdowns in numerous countries, the COVID-19 pandemic has had a negative effect on the neuromodulation market’s growth. COVID-19’s spread resulted in severe public health concerns. However, a large number of clinics and hospitals around the world have been reformed in order to improve hospital capacity and deliver better healthcare. In addition, neuromodulation sales have decreased across multiple regions due to a fall in both new patient and service implant procedures. Plenty of people who otherwise would have gotten tested for their mental illnesses has had to avoid visiting hospitals because of the risk of the infection. In most countries around the world, only patients with severe conditions were allowed to visit hospitals since the hospital beds were all occupied by severely afflicted COVID-19 patients. Market Growth Factors Rising Demand for Deep Brain Stimulation Deep brain stimulation (DBS) uses electrodes coupled to a pulse generator implanted in the patient’s body to continuously administer low bipolar or monopolar electric impulses, activating a tiny portion of the brain. DBS is used to treat pain, epilepsy, movement disorders like tremors, Parkinson’s disease, dystonia, and psychiatric disorders like Tourette syndrome, obsessive-compulsive disorder, and depression, among others. Manufacturers are now working to improve their existing DBS systems while also designing the next generation of devices. DBS is being targeted to different parts of the brain by researchers, who are testing the treatment on distinct groups of Parkinson’s patients. Rising Incidence of drug resistant chronic conditions A considerable number of the patient population suffering from chronic illnesses such as chronic back pain, depression, epilepsy, and sleep apnea, among others, is displaying medication and drug resistance. Resistance manifests itself in the form of slow treatment progression and delayed or limited effects. As a result, healthcare professionals are focusing more on neurostimulation techniques for the treatment of chronic illnesses, which is propelling the neuromodulation devices market forward. Epilepsy, treatment-resistant depression, and other chronic diseases impose a significant financial burden on countries in terms of patient treatment. Market Restraining Factors Low Diagnosis and Treatment Rates in Developing Countries In developing countries, the prevalence of neurological diseases such as epilepsy, depression, and others is increasing at an incredible rate. Despite having a substantially larger frequency, emerging countries have lower diagnostic rates, which limits the number of individuals who require treatment. Lower diagnosis rates in these nations are attributed to a variety of causes, including a lack of public awareness and limited access to diagnostic facilities due to inadequate healthcare infrastructure. Low income is also one of the leading factors which forbid some people from visiting the hospital and getting tests done to arrive at the correct diagnosis. Technology Outlook Based on Technology, the market is segmented into Internal and External. The internal segment acquired the largest revenue share in the neuromodulation market in 2021. The significant demand for this technology is due to the growing incidence rate of the chronic leg, back, and arm pain, as well as the applicability of this technology in the effective management of these chronic pains. Due to an increase in the incidence of Parkinson’s disease and an increase in product approval for neurological disease treatment, the internal modulation technology would be in demand in the upcoming years. Biomaterial Outlook Based on Biomaterial, the market is segmented into Metallic, Polymeric, and Ceramic. The polymeric segment procured a substantial revenue share in the neuromodulation market in 2021. Polymeric biomaterials (biopolymers) are materials that can be employed for long or short periods of time in physiological conditions. Polymeric biomaterials cover the widest range of synthetic and hybrid materials now employed in medicine. This factor is increasing the growth of this segment of the neuromodulation market. Application Outlook Based on Application, the market is segmented into Chronic Pain, Urinary & Fecal Incontinence, Migraine, Failed Back Syndrome, Parkinson Disease, Epilepsy, Tremor, Depression, and Others. The chronic pain segment acquired the largest revenue share in the neuromodulation market in 2021. Due to an increase in the prevalence of chronic disease and increased R&D activity in the healthcare sector, the demand for neuromodulation in rapidly surging. In addition, the increasing adoption of sedentary lifestyle in people all over the world is one of the major factors that is increasing the instances of chronic pain in these people. This factor would play a major role in accelerating the growth of this segment. Regional Outlook Based on Regions, the market is segmented into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa. North America acquired the largest revenue share in the neuromodulation market in 2021. The significant growth of the regional market is attributed to the rise in prevalence of neurological diseases, the presence of key players in the regional neuromodulation market, and well-established infrastructure in the region. The presence of key market players and large pharmaceutical and biopharmaceutical industries, as well as increased investments in the country for the adoption of innovative technologies, is likely to support the regional market’s expansion. The major strategies followed by the market participants are Approvals and Trials. Based on the Analysis presented in the Cardinal matrix; Abbott Laboratories is the forerunners in the Neuromodulation Market. Companies such as MicroTransponder Inc., Boston Scientific Corporation are some of the key innovators in the Market. The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Medtronic PLC, LivaNova PLC, Boston Scientific Corporation, Abbott Laboratories, Nevro Corporation, NeuroSigma, Inc., NeuroPace, Inc., Neuronetics, Inc., MicroTransponder Inc., and Bioventus Inc. Recent Strategies deployed in Neuromodulation Market Partnerships, Collaborations, and Agreements Jun-2021: NeuroSigma entered into a partnership with KT Corporation, a telecommunication company based in South Korea. The partnership aimed at developing and commercializing, inside and outside of Korea, electronic therapies treating neurological and neuropsychological disorders, such as depression, ADHD, and epilepsy. Through this partnership with NeuroSigma, KT supported the design and development of the next-generation category of eTNS products integrating big data, artificial intelligence (AI), and cloud capabilities. Additionally, KT also supported advanced monitoring and AI analysis services, offered via its digital healthcare platform, and the commercialization and manufacturing partnerships in Korea. Feb-2020: LivaNova teamed up with Verily, an Alphabet company. The collaboration aimed at capturing measures of depression within its RECOVER clinical study, which was analyzing the efficacy of Vagus Nerve Stimulation Therapy (VNS Therapy) for difficult-to-treat Depression (DTD). Under the collaboration with Verily, LivaNova built on its work to study depression and understand the complicated elements that contribute to the disorder, improving its capacity to treat patients who have it. Oct-2019: NeuroSigma entered into a partnership with Teijin Limited, a chemical, pharmaceutical, and information technology company based in Japan. The partnership granted Teijin Pharma, Teijin’s healthcare business, exclusive rights to NeuroSigma’s TNS patent rights in Japan related to attention deficit hyperactivity disorder (ADHD), and market the Monarch eTNS System for the non-invasive treatment of ADHD in Japan. Approvals and Trials Mar-2022: Bioventus received FDA approval for the next generation StimRouter Neuromodulation System. This system is used for the therapy of chronic pain of peripheral nerve origin, excluding craniofacial pain. The newly approved StimRouter system offers a similar clinically tested, long-term pain relief while substantially improving the patient’s control and user experience. Jan-2022: Nevro received FDA approval for expanded labeling for its Senza Spinal Cord Stimulation (SCS) System for the treatment of Non-Surgical Refractory Back Pain (NSRBP). The SENZA-NSRBP study participants who were given 10 kHz Therapy showed great improvements in function, pain relief, awareness of positive change in quality of life, and reduction in everyday opioid use versus Conventional Medical Management. Aug-2021: MicroTransponder received FDA approval for Vivistim paired VNS system for chronic ischemic stroke rehabilitation. This system, Vivistim electrically stimulates the vagus nerve to decrease deficiencies in upper limb and extremity motor function and to enhance patients’ capacity to move their arms and hands. Under the skin in the patient’s chest, an implantable pulse generator is implanted with a lead wire that leads up to electrodes placed on the left side of the neck where the vagus nerve is. Jun-2021: LivaNova received FDA approval for proceeding with its, “Treating Obstructive Sleep Apnea using Targeted Hypoglossal Neurostimulation (OSPREY)”, an investigational device exemption (IDE) clinical study. The aura6000 was developed to sustain muscle tone of the tongue and upper airway so that airway blockage and resulting sleep apnea are substantially decreased or removed. The OSPREY study was used to analyze the apnea-hypopnea index responder rate of subjects with device stimulation activated to decide whether it is statistically higher than the rate of subjects without stimulation. The overall safety and efficacy of the device in its ability to treat patients with OSA were evaluated. Acquisitions and Mergers Aug-2021: Medtronic acquired Intersect ENT, a world leader in ear, nose, and throat (ENT) medical technology devoted to transforming patient care. The acquisition enabled Medtronic to expand its portfolio of products used during ear, nose, and throat procedures. The complementary customer base and product lines would further enhance Medtronic’s efforts to have a positive impact on patients who suffer from chronic rhinosinusitis (CRS). Mar-2021: Bioventus completed the acquisition of Bioness, a key player in neuromodulation and rehabilitation medical equipment through its ingenious peripheral nerve stimulation therapy and premium rehabilitation solutions. The acquisition matched Bioventus’ goal of assisting patients to regain active lifestyles and the strategy of accretive revenue growth through acquisitions that leverage the Company’s existing infrastructure. Jan-2020: Medtronic completed the acquisition of Stimgenics, the pioneer of a new spinal cord stimulation (SCS) waveform known as Differential Target Multiplexed (DTM) Spinal Cord Stimulation. The therapy is a novel and distinctive programming option to treat patients with chronic pain. It is delivered via the Medtronic Intellis platform. The DTM waveform had a more significant impact on the neural-glial interaction than other frequencies. Product Launches and Product Expansions May-2022: Medtronic unveiled CareGuidePro, a smartphone application and web portal. CareGuidePro is Medtronic’s foremost patient-centric digital health system designed for spinal cord stimulation patients, planned as a seamless solution that would merge into the care provider’s workflow. This digital health system paves the way for a more engaging and informative patient experience that results in a better physician-patient dialogue, leading to improved therapy management. Mar-2021: Abbott launched NeuroSphere Virtual Clinic, an unparalleled technology that permits patients to communicate with physicians, ensure proper settings and functionality, and receive new treatment settings remotely as required. Through this product, Physicians can communicate and digitally prescribe new stimulation settings remotely, enabling them to expand care beyond their clinic walls and optimize therapy management using NeuroSphere Virtual Clinic. Geographical Expansions Mar-2022: Boston Scientific Corporation expanded its geographical footprint by launching its R&D Center in Pune. The expansion aimed to capitalize on the country’s R&D expertise and offer varied opportunities for engineers and innovators in India. The R&D Center provided expertise to all of the company’s therapy areas, specifically peripheral interventions, interventional cardiology, cardiac rhythm management, neuromodulation, endoscopy, and urology and pelvic health. The R&D team provided support in the fields of software engineering, mechanical design, and analysis, sustaining engineering, quality, and compliance. Scope of the Study Market Segments covered in the Report: By Technology • Internal • External By Biomaterial • Metallic • Polymeric • Ceramic By Application • Chronic Pain • Urinary & Fecal Incontinence • Migraine • Failed Back Syndrome • Parkinson Disease • Epilepsy • Tremor • Depression • Others By Geography • North America o US o Canada o Mexico o Rest of North America • Europe o Germany o UK o France o Russia o Spain o Italy o Rest of Europe • Asia Pacific o China o Japan o India o South Korea o Singapore o Malaysia o Rest of Asia Pacific • LAMEA o Brazil o Argentina o UAE o Saudi Arabia o South Africa o Nigeria o Rest of LAMEA Companies Profiled • Medtronic PLC • LivaNova PLC • Boston Scientific Corporation • Abbott Laboratories • Nevro Corporation • NeuroSigma, Inc. • NeuroPace, Inc. • Neuronetics, Inc. • MicroTransponder Inc. • Bioventus Inc. Unique Offerings • Exhaustive coverage • Highest number of market tables and figures • Subscription based model available • Guaranteed best price • Assured post sales research support with 10% customization free Read the full report: https://www.reportlinker.com/p06283452/?utm_source=GNW About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________
Crispr Therapeutics Chief Executive Sam Kulkarni says the next two years of clinical trials and data readouts will give investors, and patients, plenty to cheer about.
The number of companies stepping up to cover travel costs for U.S. employees seeking abortion services is growing following a decision by the U.S. Supreme Court on Friday to overturn its landmark Roe v. Wade.
The FDA has been banned Juul from the U.S. markets on safety and marketing concerns.
NYPD officials provided an update Thursday evening after a detective was injured in a shooting in Brooklyn.
(Reuters) -Sales of Juul e-cigarettes were blocked by the U.S. Food and Drug Administration on Thursday, in a major blow to the once high-flying firm whose products have been tied to a surge in teenage vaping. Some of the findings raised concerns due to insufficient and conflicting data, including whether potentially harmful chemicals could leach out of the Juul pods, the FDA said. "We respectfully disagree with the FDA's findings ... intend to seek a stay and are exploring all of our options under the FDA's regulations and the law, including appealing the decision and engaging with our regulator," said Joe Murillo, chief regulatory officer at Juul.
"It has been 16 years, but I can still hear myself begging my mother, my doctor, not to make me do this ― please don’t make me do this."
Children older than 6 months are now eligible to receive vaccinations at the county's June 29 pop-up clinic in Kewanee
There is need for intensified surveillance in the broader community, WHO Director-General Tedros Adhanom Ghebreyesus said on Thursday, adding that cases in non-endemic countries were still predominantly among men who have sex with men. "Person-to-person transmission is ongoing and is likely underestimated," Tedros said at a meeting of the International Health Regulations (2005) Emergency Committee. Forty eight countries have reported cases in the current outbreak, which began in May.
You know the healthy habits you need to adopt to protect your heart, but were you aware certain lifestyle changes can keep your brain healthy, reducing your risk of age-related disorders like dementia? They include diet, exercise, and according to a new study, making sure you're getting enough of this vitamin on a daily basis. Read on to find out more—and to ensure your health and the health of others, don't miss these Sure Signs You've Already Had COVID. 1 What The Study Found According to a ne
New York City accounts for over 20% of nationwide monkeypox cases, so the city health department is offering Bavarian Nordic's Jynneos vaccine to more people
The North Carolina Department of Health and Human Services reported the first case of monkeypox in the state.
The disease is spread through close contact and can affect anyone
Photo Illustration by Kelly Caminero/The Daily Beast/Getty/ShutterstockThe monkeypox outbreak that health authorities first noticed in Europe back in May is getting worse. According to the World Health Organization’s latest report, there are over 2,100 confirmed cases, and at least one person has died.Now geneticists finally have enough data to begin getting a handle on how exactly the outbreak started—and where it might be heading.It’s not good news. Monkeypox, a viral disease that causes fever
Biogen Inc. said in a statement that it stopped a post-marketing clinical trial testing its Alzheimer's disease therapy Aduhelm, citing a Medicare policy that will limit usage of the drug. The company updated the study's ClinicalTrials.gov
An advisory panel for the Centers for Disease Control and Prevention (CDC) on Thursday gave the green light to Moderna’s coronavirus vaccine for kids aged 6 through 17, bringing it closer to becoming the second vaccine in the U.S. eligible for use in children. The CDC’s Advisory Committee on Immunization Practices (ACIP) on Thursday unanimously…
Everyone has bad habits, but there's some behaviors we do that are actually more harmful than we think. Unhealthy habits can have long-term negative consequences and Dr. Charles Tabone N.M.D a Naturopathic Medical Doctor with Pause Studio tells us five things people do on a regular basis that should be stopped immediately. Read on to find out more—and to ensure your health and the health of others, don't miss Already Had COVID? These Symptoms May "Never Go Away". 1 Don't Throw Caution to the Win
‘All is well with Fauci’ the White House's chief medical adviser said during a COVID-19 Response Team briefing, He also took Paxlovid to treat his COVID case.
The U.S. Supreme Court issued a major decision on abortion today, overturning Roe v. Wade and declaring that the U.S. Constitution doesn't guarantee the right to abortion. In the 6-3 ruling, the Supreme Court ruled that the Constitution "makes no reference to abortion" and that "no such right is implicitly protected by any constitutional provision." Writing the majority opinion, Justice Samuel Alito -- joined by the court's other conservative justices, including Brett Kavanaugh and Amy Coney Barrett -- tossed out Roe as well as Planned Parenthood v. Casey, a 1992 Supreme Court decision upholding abortion rights.
Some 13 U.S. states have 'trigger laws' to immediately ban abortion in the wake of Roe's reversal.
He is in the intensive-care unit at a local hospital, according to local media reports.